TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03163797

Intervention type: DIAGNOSTIC_TEST
Intervention: PET/MRI for evaluation
Description: Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test. They will also undergo low dose chest CT on the same day before PET/MRI. In the posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation. Thereafter, the patients will then be followed up also with alternative extend-field CT and whole body MRI by every 6 months. If tumor recurrence is confirmed or highly suspected, PET/MRI will also be performed for tumor re-staging.
Study: NCT01438580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 100mg aspirin was administrated every day
Study: NCT01172717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
Study: NCT02487017

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Transcatheter Arterial Chemoembolization (TACE)
Description: Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC-CIK
Description: Transcatheter Arterial Chemoembolization (TACE):~5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min~DC-CIK:~8×10\^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32
Study: NCT01419652

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hold hypoglycemic meds
Description: continue versus hold hypoglycemic medications
Study: NCT02639000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo transfer
Description: Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
Study: NCT04360759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine or hydroxychloroquine
Description: Chloroquine has in vitro antiviral activity against many viruses, including SARS-CoV-1 and SARS-CoV-2. Chloroquine inhibits coronavirus replication at in vitro concentrations that are not cytotoxic and within a range of blood concentrations achievable during standard antimalarial treatment. Chloroquine inhibits viral replication through interference with glycosylation of coronavirus ACE2 receptors, required for viral entry, and downstream phagolysosome alkalisation, interfering with the low-pH-dependent steps of viral fusion and uncoating. Chloroquine also has anti-inflammatory properties and could provide benefit through this mechanism in Covid-19, where a cytokine storm has been described in critically ill patients. Hydroxychloroquine is a less toxic metabolite of chloroquine, has similar anti-inflammatory properties, and is more potent against SARS-CoV-2 in vitro.
Study: NCT00978315

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
Study: NCT03122951

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ovulation test use
Description: Normal use of The Clearblue® Advanced Ovulation Test according to Information for use instructions
Study: NCT02912858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: geko plus R-2
Description: The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.~The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies.
Study: NCT04176484

Intervention type: OTHER
Intervention: Survey
Description: Women age 25 and above who are scheduled for an abdominal procedure and were seen in the General Surgery Clinic will be called and asked to complete a 5-10 minute verbal survey prior to their date of surgery. Some additional information will be gleaned from the medical record during the interview.
Study: NCT00978315

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Miglyol oil
Description: Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
Study: NCT01501305

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Mineral solution
Description: Rehydration mineral solution

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carob powder with probiotics
Description: 7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
Study: NCT03371615

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anti-regurgitation infant formula
Description: Anti regurgitation infant formula

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anti-regurgitation infant formula
Description: Anti regurgitation infant formula
Study: NCT03358888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal with as needed opioids
Description: Multi-modal with as needed oxycodone and tramadol provided for break-through pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal with one week of opioids offered
Description: Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
Study: NCT00436371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: Oral tablets
Study: NCT04441229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABMT mobile application
Description: After consent/assent, participants will complete 1 hour-long, in-person or remote, baseline study visit at the Multiple Sclerosis Comprehensive Care Center. During this visit, participants will complete baseline study surveys and a brief computerized attention bias assessment and be trained on the use of the ABMT mobile application. Participants will then complete at-home game play 4 days a week, for 30 days, using an iOS mobile device, approximately 10-15 minutes each day. Subjects will complete weekly online study surveys via REDCap or MyCap (Mobile REDCap Application). At the conclusion of participation, participants will complete online end of study surveys via REDCap or MyCap.~Parents of participants will complete surveys at the baseline visit, followed by online surveys at Week 2 and at the end of study. For participants who are 18 years old or older, parental participation will not be required.
Study: NCT00091806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab (ABX-EGF)
Description: 6 mg/kg once every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 9 mg/kg once every 3 weeks
Study: NCT04073771

Intervention type: DEVICE
Intervention: Continuous renal replacement therapy with oXiris
Description: Continuous renal replacement therapy with oXiris in patient with septic shock
Study: NCT03608176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PASO diet group
Description: This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol. They will also be instructed to consume green tea (2 cups/day for 3 days/week), black tea (2 cups/day for 2 days/week), coffee (2 cups/day for 2 days/week), cinnamon (1 tsp/day for at least 3 days/week), psyllium fiber (3 tsp/day/week) and water (1.5 L/day/week).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-fat diet group
Description: This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: Waiting list group
Description: This group will only receive written information with recommendations on healthy eating. When the study finished, this group will receive a behavioral change protocol with a low-fat, low calorie diet.
Study: NCT02534701

Intervention type: DEVICE
Intervention: ERIC® and SOFIA™
Description: a self-expanding clot retrieval system
Study: NCT01075555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pravastatin sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sorafenib tosylate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study: NCT02231554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feldenkrais Method
Description: The program of Awareness Through Movement ® chosen for this study, teaches the basic movements of the column. The aim is to stimulate changes in the chronic pathological patterns and in the distorted kinesthetic perceptions that so often hinder the rehabilitation of chronic non-specific low back pain. The patients will be treated in outpatient with the Feldenkrais method. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Back School
Description: The rehabilitation program of Back School is divided into two parts: one theoretical and one practical. To obtain an effective action not only in reducing pain but also in preventing relapse, the Back School acts on the typical risk factors of chronic non-specific low back pain, such as incorrect postures and movements, psychological stress, poor physical fitness, overweight, obesity, smoking, and insufficient knowledge of the spine. The patients will be treated in outpatient with a Back School program. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
Study: NCT02940509

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine plus Magnesium sulfate
Description: Patients will receive 2 IV infusions:~1. Ketamine (0.5mg/kg)~2. Magnesium sulfate (2g)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
Study: NCT04796090

Intervention type: OTHER
Intervention: Clinical assessment
Description: FSFI, ASEX and FSDS scores were compared between the adolescents with (Study group) or without (Control group) genital warts.

Intervention type: OTHER
Intervention: Clinical assessment
Description: FSFI, ASEX and FSDS scores were compared between the adolescents with (Study group) or without (Control group) genital warts.
Study: NCT01148992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine
Description: 0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
Study: NCT02227680

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Therapy
Description: Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage Therapy
Description: Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
Study: NCT01148992

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0mg
Study: NCT05186142

Intervention type: OTHER
Intervention: Ultrasonography / Ultrasound elastography
Description: Ultrasonography / Ultrasound elastography
Study: NCT03537027

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: In total 20 pills will be taken by the subjects, each containing 100 micrograms of vitamin D3, resulting in the total amount of 2000 micrograms of vitamin D3. Of the 20 pills, 10 will be taken in the morning with breakfast and 10 with lunch.
Study: NCT02544308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Experimental Arm
Study: NCT04348916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCR-177
Description: Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCR-177
Description: Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCR-177
Description: Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1
Study: NCT02544308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Experimental Arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No further treatment
Description: Comparator Arm
Study: NCT04348916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCR-177
Description: Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCR-177
Description: Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1
Study: NCT03134352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-3101
Description: A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
Study: NCT04348916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ONCR-177
Description: Intratumorally administered oncolytic immunotherapy comprised of a genetically engineered HSV-1

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Anti-PD-1 monoclonal antibody
Study: NCT03134352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-3101
Description: A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
Study: NCT04203615

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial magnetic stimulation- sham rTMS
Description: Transcranial magnetic stimulation- sham figure-eight coil will be used for stimulation. This sham coil will generate only clicking noise and will not generate any magnetic field.
Study: NCT04348916

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Anti-PD-1 monoclonal antibody
Study: NCT04203615

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial magnetic stimulation- real rTMS
Description: Transcranial magnetic stimulation- figure-eight coil will be used for stimulation. 1 Hz stimulation, 100% of Resting Motor Threshold will be used.
Study: NCT00686114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135mg/m2, day 1 and day 29 of the radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135mg/m2, day 1 and day 29 of the radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 135mg/m2, day 1 and day 29 of the radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 135mg/m2, day 1 and day 29 of the radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tarceva
Description: 150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tarceva
Description: 150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
Study: NCT04307290

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride, or Saline
Description: drug infusion from 10 min before the start of surgery to the end of surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride, or Saline
Description: drug infusion from 10 min before the start of surgery to the end of surgery
Study: NCT01588795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous renal denervation and TMNS
Description: Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
Description: Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
Study: NCT00686114

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Enlarged field radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Enlarged field radiotherapy
Study: NCT01701570

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Attention Control
Description: The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Training
Description: The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
Study: NCT00686114

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Conventional field radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Conventional field radiotherapy
Study: NCT01182090

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposacropexy
Description: In open approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colposacropexy
Description: In laparoscopic approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
Study: NCT01163227

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (single and multiple doses)
Study: NCT01959711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior RA
Description: Posterior retroperitoneoscopic adrenalectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral transperitoneal LA
Description: Lateral transperitoneal laparoscopic adrenalectomy
Study: NCT03926663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine, a potent α-2 adrenoceptor agonist, is approximately 8 times more selective toward the α-2 adrenoceptors than clonidine.~Patients will receive 0.25% bupivacaine (with an average dose of 1-1.5 mg/kg) + 0.2 μg/kg dexmedetomidine preincisional local infiltration of the nasal mucosa.
Study: NCT01163227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051 2 mg (single and multiple doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051 15mg (single and multiple doses)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQW051 100mg (single dose), and 50mg (multiple doses)